Ultragenyx CFO Howard Horn sells $107,897 in company stock

Howard Horn, Chief Financial Officer at Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), sold 7,066 shares of the company’s common stock on October 15, 2026. The transaction totaled $107,897.

The shares were sold at a price of $15.27 per share. This sale represents shares disposed of to cover required tax withholdings associated with the vesting of restricted stock units (RSUs). The stock currently trades at $14.96, down 55% over the past year, with shares recently touching a 52-week low of $12.73.

Following this transaction, Mr. Horn directly owns 89,229 shares of Ultragenyx common stock. This figure includes previously reported shares of common stock underlying RSUs that are subject to certain vesting conditions.According to InvestingPro analysis, the stock appears undervalued at current levels, with the company’s next earnings report scheduled for November 4. Investors can access comprehensive analysis and Fair Value estimates on InvestingPro, along with additional ProTips for RARE.

In other recent news, Ultragenyx Pharmaceutical announced significant developments that are capturing investor attention. The company disclosed the sale of a Rare Pediatric Disease Priority Review Voucher for $210 million, which it received following FDA approval of GENGLYCOS for glycogen storage disease type Ia. This strategic move has been complemented by the FDA’s approval of FAYUVI, a gene therapy for pediatric patients with mucopolysaccharidosis type IIIA, marking it as the first-ever treatment for Sanfilippo syndrome Type A. Analysts at H.C. Wainwright have reiterated a Buy rating for Ultragenyx, maintaining a $25 price target in light of these developments.

Furthermore, Cantor Fitzgerald and Canaccord both raised their price targets for Ultragenyx shares to $39, reflecting optimism following the regulatory approval of FAYUVI. Cantor Fitzgerald maintained an Overweight rating, while Canaccord kept a Buy rating. This FDA approval represents Ultragenyx’s second gene therapy approval, underscoring the company’s advancements in addressing rare genetic conditions. These recent achievements highlight Ultragenyx’s continued progress in the biopharmaceutical sector.